ONO-7579 / Ono Pharmaceutical - LARVOL DELTA

Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-TRK Inhibitor, in a Murine Xenograft Tumor Model. (PubMed, J Pharmacol Exp Ther) - "This research found that phosphorylated TRKA was a useful biomarker for explaining the antitumor efficacy of TRK inhibitors using a PK/PD modeling approach in xenograft mice. This finding suggests a rational dosing regimen in early-stage clinical studies for ONO-7579 , a novel pan-TRK inhibitor."

Journal • PK/PD data • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors (clinicaltrials.gov) - P1; N=1; Terminated; Sponsor: Ono Pharmaceutical Co. Ltd; Phase classification: P1/2 ➔ P1

Clinical • Phase classification